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Background: Inosine triphosphate pyrophosphohydrolase (ITPase) is a ‘house-cleaning’ enzyme that degrades non-
canonical (‘rogue’) nucleotides. Complete deficiency is fatal in knockout mice, but a mutant polymorphism resulting
in low enzyme activity with an accumulation of ITP and other non-canonical nucleotides, appears benign in
humans. We hypothesised that reduced ITPase activity may cause acquired mitochondrial DNA (mtDNA) defects.
Furthermore, we investigated whether accumulating mtDNA defects may then be a risk factor for cell
transformation, in adult haematological malignancy (AHM).
Methods: DNA was extracted from peripheral blood and bone marrow samples. Microarray-based sequencing of
mtDNA was performed on 13 AHM patients confirmed as carrying the ITPA 94C>A mutation causing low ITPase
activity, and 4 AHM patients with wildtype ITPA. The frequencies of ITPA 94C>A and IVS2+21A>C polymorphisms
were studied from 85 available AHM patients.
Results: ITPA 94C>A was associated with a significant increase in total heteroplasmic/homoplasmic mtDNA
mutations (p<0.009) compared with wildtype ITPA, following exclusion of haplogroup variants. This suggested that
low ITPase activity may induce mitochondrial abnormalities. Compared to the normal population, frequencies for
the 94C>A and IVS2+21A>C mutant alleles among the AHM patients were higher for myelodyplastic syndrome
(MDS) - but below significance; were approximately equivalent for chronic lymphoblastic leukemia; and were lower
for acute myeloid leukemia.
Conclusions: This study invokes a new paradigm for the evolution of MDS, where nucleotide imbalances produced
by defects in ‘house-cleaning’ genes may induce mitochondrial dysfunction, compromising cell integrity. It supports
recent studies which point towards an important role for ITPase in cellular surveillance of rogue nucleotides.
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During purine nucleotide synthesis in cells, the non-
canonical nucleotide inosine triphosphate (ITP) can be
synthesized from inosine monophosphate (IMP) by the
sequential actions of monophosphate kinase and nuc-
leoside diphosphate kinase. ITP pyrophosphohydrolase
(ITPase) catalyses the conversion of ITP back to IMP
forming a ‘futile cycle’ (Figure 1) [1]. Importantly, ITPase
also acts as a house-cleaning enzyme by degrading other
‘rogue’ purine nucleotides in cells, e.g., endogenous
deoxy-inosine triphosphate (dITP) and deoxy-xanthosine
triphosphate (dXTP) [2-4]. In addition, exogenous nucle-
otides derived from purine drugs, such as thio-ITP and
methyl-thio-ITP derived from thiopurines, are substrates
for ITPase [5]. More recently it has been shown that low
ITPase appears to protect against ribavirin-induced
hemolytic anaemia, possibly through a mechanism that
binds ribavirin as its rogue nucleotide form [6].
Knockout studies of ITPase in the mouse have shown
that deficient mice show severe growth retardation and
die before weaning [7], which was attributed to accumu-
lation of mutagenic dITP in cellular deoxy-nucleotide
pools [8]. But despite a critical role in the surveillance of
rogue nucleotides, genetically low ITPase activity in
humans is relatively common and has been assumed to
be clinically benign, presenting only as an autosomal re-
cessive red cell enzymopathy. Abnormal accumulation of
ITP in humans who have low ITPase activity has been
shown to occur in both erythrocytes and leucocytes, im-
plying that inherited low ITPase occurs in all tissues [9].
Interestingly, ITPA has been mentioned in relation to
hematological disease where it has been noted as one of
five mixed-lineage leukemia associated genes whose up-
regulation accompanies amplification of the MLL gene
region of 11q23 [10]. Further evidence has been pro-
vided by a recent in vitro study on human HeLa cells,
with a knockdown ITPA gene, which showed that theFigure 1 Overview of purine metabolism and ITPase ‘futile
cycle’. ITPase: Inosine triphosphate pyrophosphohydrolase; IMP:
Inosine monophosphate; XMP: Xanthosine monophosphate; GMP:
Guanosine monophosphate; dITP: deoxy-Inosine triphosphate; AMP:
Adenosine monophosphate.absence of functional ITPase activity can lead to accu-
mulation of non-canonical nucleotides which may cause
DNA damage and cancer [11].
Five single polymorphic sequence variants in the human
ITPA gene have been identified, two of which are associa-
ted with ITPase loss of activity (94C>A in exon-2, and
IVS2+21A>C). These interact and affect branch points
resulting in missplicing of exons 2 and 3 leading to short-
ening of polypeptide stretches in the enzyme [12]. The
other three coding region ITPA polymorphic sequence var-
iants are silent mutations (138G>A, 561G>A and 708G>A)
[3]. Homozygosity of the ITPA 94A allele, which results in
deficiency of ITPase activity in erythrocytes and lympho-
cytes, occurs in approximately 1 in 1000 Caucasians [3].
Carriers represent about 1 in 15 (6.0%) of Caucasian popu-
lations, and have an average red cell ITPase activity of
about 22% of normal. This allele is more common in Asian
populations, with a frequency of 11-15% [13]. Homozygo-
sity of the ITPA IVS2+21C allele occurs in approximately 1
in 250 Caucasians, with a carrier frequency of about 1 in 8
(13.0%), resulting in partial reduction of ITPase activity
with an average of 60% normal levels in red cells. Its fre-
quency varies greatly in other populations, e.g. the SNP
is absent among Japanese. Compound heterozygotes
(ITPA 94A/IVS2+21C) have 10% of normal activity.
Mitochondria are synthesized from both nuclear genes
that encode mitochondrial proteins and from a small
number of genes encoded by the mitochondrial genome
(mtDNA) [14]. The high mutation rate associated with
mtDNA is thought to be the result of inappropriate in-
corporation of rogue nucleotides into the mtDNA [15]
which may be caused by: (a) exposure to high concentra-
tions of reactive oxygen species (ROS) generated in the
mitochondria from the electron transfer system [16], or
(b) lack of histone protection of the mitochondrial gen-
ome [17]. Repair mechanisms for mtDNA were thought
to be limited [18-20], but mitochondria appear to have
mechanisms that respond to mtDNA damage - rather
than to genotoxic stress by itself - and re-localize repair
proteins from the cytosol to the organelle [21]. These in-
clude imported mechanisms for base excision repair,
now considered to include long-patch as well as short-
patch, and mismatch repair [22].
Mitochondria with differing genetic backgrounds
(heteroplasmy) can coexist within a cell or tissue [20],
but during cell division the proportions of differing
mitochondria segregating into new cells may change,
resulting in some cases with daughter cells receiving
only one type of mitochondria, i.e., homoplasmy [18].
Where harmful mtDNA mutations occur, segregation of
the ‘mutant’ mitochondria may result in their accumula-
tion in a significant percentage of the cells in a tissue,
which may result in sufficient dysfunction to cause di-
sease, once a critical threshold is reached [23]. For
Table 1 Characteristics of a cohort of 85 adult
hematological malignancy patients participating in this
study
Attributes MDS CLL AML
Number 39 28 18
Age (year): 75 (54–90) 68 (37–84) 69 (39–85)
median (range)
Sex: (Male/Female) 22/17 21/7 7/11
Sample type:
Peripheral blood 30 23 17
Bone marrow 9 5 1
Classification (n) RAEB (n=3),
RAEB-1 (n=3),
CLL (n=28) AMLAMDS (n=9),
RAEB-2 (n=7),
MDP5q (n=1),
AMLDN (n=6),
RCMD (n=13),
MDSU (n=2),
AML16 (n=1),
AML/TLD (n=2)
RA (n=1),
RARS(n=2),
CMML (n=6),
CMML-1 (n=1)
MDS: Myelodysplastic syndromes; RA: Refractory anaemia; RARS: Refractory
anaemia with ringed sideroblasts; RAEB: Refractory anaemia with excess blasts;
RCMD: Refractory cytopenia with multilineage dysplasia; MDSU:
Myelodysplastic syndrome unclassifiable; MDP5q: Myelodysplastic syndrome
associated with isolated (del)5q chromosomal abnormality; CMML: Chronic
myelomonocytic leukaemia; AML: Acute myeloid leukaemia; AML/TLD: Acute
myeloid leukaemia with trilineage dysplasia; AMLAMDS: Acute myeloid
leukaemia with multilineage dysplasia with prior myelodysplasia; AMLDN:
Acute myeloid leukaemia with multilineage dysplasia without prior
myelodysplasia; AML16: AML with abnormal bone marrow eosinophils (inv)16
(p13q22) or t(16;16)(p13;q22); (CBFb/MYH11); CLL: Chronic
lymphocytic leukaemia.
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can result in rapid accumulation of mutations and dele-
tions which lead to mitochondrial failure and cell apop-
tosis. Progression of the mitochondriopathy can lead to
multi-organ involvement. This is exemplified by mitochon-
drial neurogastrointestinal encephalomyopathy (MNGIE)
[24], which arises from a nucleotide imbalance caused by
mutation of nDNA-encoded enzyme thymidine phospho-
rylase (TP) that is imported into mitochondria [25].
No direct cause-effect relationship has been established
between mitochondrial mutation and haematological ma-
lignancy. Nonetheless, progression of haematological ma-
lignancy is characterised by mtDNA mutations with a low
heteroplasmic mutation load in early stages of myelodys-
plastic disease (MDS); however advanced stages of MDS
are accompanied by a dramatic increase in the mtDNA
mutations, reaching homoplasmy with acute myeloid
leukemia (AML) [26].
Mutations in genes which produce metabolic imba-
lances or unusual types of nucleotides are thought to
represent risk factors for the development of cancers,
particularly where chromosome rearrangement or gene
instability is implicated [27,28]. This is supported by a
recent study of ITPase deficient mouse embryonic fibro-
blasts, which has linked rogue nucleotides produced by
reduced ITPase activity to an increase of chromosomal
abnormality frequency and accumulation of single-
strand breaks in nuclear DNA (nDNA) [8].
We hypothesised that because of its role in rogue nu-
cleotide surveillance, reduced ITPase activity may be det-
rimental to tissue mitochondrial health by accumulation
of mtDNA defects, from chronic exposure to endogenous
rogue nucleotides (ITP/dITP/XTP). We focused on de-
fects found in mitochondria because surveillance and
repair of mtDNA is relatively lacking compared to gen-
omic DNA.
Furthermore, we hypothesized that the effect would be
cumulative with time, i.e. more prevalent in adults. We
also considered whether compromise of mitochondrial
function may then be a risk factor for cell transforma-
tion. Several types of adult haematological malignancy
(AHM) are already known to be related to nDNA muta-
tions. Thus, to study mtDNA changes we focused on
chronic lymphocytic leukemia (CLL), AML and MDS
because of their relative frequency and association with
DNA repair pathologies [29,30].
Methods and materials
Patient samples
Table 1 shows the patient characteristics for the samples
used. In this pilot study, all suitable patient samples be-
longing to 3 disease groups, MDS (n=39), CLL (n=28)
and AML (n=18), as available in Brisbane, were obtained
from the Australasian Leukaemia and Lymphoma GroupTissue Bank, Princess Alexandra Hospital, and the
Hematology Clinic at Mater Adult Hospital. DNA was
extracted from a total of 85 peripheral blood or bone
marrow samples. Patients were selected on the basis of:
(a) Caucasian - to minimize differences in rates of ITPA
sequence variants known to occur between some races
[13]; (b) untreated or not participating in any trials, i.e.
the disease was not secondary to prior drug therapy for
malignancy; (c) age-onset haematological disease. The
study was approved by the Tissue Bank Human Ethics
Review Committee (HREC) and by the Mater Hospital
and University of Queensland HRECS.
DNA extraction and ITPA (PCR) amplification
DNA was extracted using a QIAamp DNA Blood Mini
kit (Qiagen, Valencia, CA). The ITPA 94C>A and IVS2
+21A>C sequence variants were screened by standard
PCR using primers to amplify exons 2, 3 and 4 and the
intervening sequences (introns), by a method modified
from Sumi et al., [3]. Identification of sequence variants
was performed by sequencing of the amplified regions,
using BigDyeW terminator v3.1 cycle sequencing, as per
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v2.31 and ChromasPro v1.42 software.
Complete mtDNA (PCR) amplification and purification and
affymetrix microarray protocol
The entire mitochondrial genome was analysed from the
13 AHM patients confirmed as carrying the ITPA 94A
mutant allele and from 4 randomly-selected AHM pa-
tients with the ITPA 94C wildtype allele. Analysis of
mtDNA mutations was achieved using the Affymetrix
MitoChip v2.0 resequencing array, following the manufac-
turer’s protocol [31,32]. Preparation of the mtDNA in-
volved amplifying the entire mtDNA sequence in three
overlapping long PCR fragments using TaKaRa LA Taq
(TaKaRa Biomedicals), with each reaction containing 25ng
of genomic DNA. The three primers sets are described in
the Affymetrix MitoChip v2.0 supporting documentation.
After target amplification, PCR products were purified
using a High Pure PCR Product Purification Kit (Roche,
Germany). The hybridization steps of the Affymetrix
protocol can be summarized as follows: PCR products
were pooled, to ensure equal molar amount, followed by
fragmentation and labeling of the pooled PCR products,
then hybridization for 16 hours at 49°C with 60 rpm ro-
tation in a hybridization mix solution (fragmentation and
labeling enzymes and reagents were part of the Affymetrix
GeneChip Resequencing Reagent Kit). Washing of the
MitoChip was performed using the Affymetrix Fluidics
Station 450 (Mini_DNAArray_WS5_450), and finally,
scanning the MitoChip array for the four alternative oli-
gonucleotides for each single base using Affymetrix
GeneChip Scanner 3000.
Automated batch analysis of microarray data
Data analysis of the microarrays was carried out using
Affymetrix GSEQ software. The Affymetrix MitoChip
v.2.0 is tiled with 25-mer DNA probes divided into two
sections, the first section being the Cambridge Reference
Sequence (rCRS) NC_012920 for mtDNA, while the se-
cond section comprises sequences representing 500 of the
most common haplotypes recorded in the MitoMap pub-
lic database (http://www.mitomap.org). These include
known mtDNA single nucleotide polymorphisms (SNPs)
as well as known pathological mutations, insertions, and
deletions. The Affymetrix algorithm parameter settings
recommended to achieve optimal performance were used
to analyze the mitochondrial sequences, with ‘diploid’ se-
lected as the genome model to enable the detection of
heteroplasmy. Using IUPAC codes, the GSEQ MitoChip
v2.0 microarray software will assign: homoplasmic muta-
tions with normal bases (A, C, G or T); heteroplasmic
mutations, signified by IUPAC codes R (A/G), Y (C/T/U),
K (G/T/U), M (A/C), S (C/G), or W (A/T/U); or an
N-Call where a base position cannot be assigned by thesoftware (the letter “N” in the sequence indicating signal
intensity within two standard deviations of zero “no sig-
nal”). A Quality Score Threshold (QST) of 3 provided the
highest performance in terms of overall base calling accu-
racy and call rates by the software [19].
Haplogroup analysis
The mtDNA from AHM patient samples were subjected
to haplogroup analysis to determine which of the observed
mutations could be considered genetically unique for each
patient, by removing those known to be associated with
the patient’s haplogroup (and can therefore be considered
non-pathogenic). This analysis was performed using
the freely available HaploGrep web application (http://
haplogrep.uibk.ac.at/) [33], which is based on data from
Phylotree (http://www.phylotree.org/) [34]. The remaining
unique pathogenic and non-pathogenic mtDNA muta-
tions were then considered according to the hypothesis
that the ITPA mutation causes an increase in mutagenesis
(see Additional file 1: Tables S1-S3). Non-parametric ana-
lysis (Mann Whitney two-tailed test) was then performed
for comparing the statistical significance of differences in
mtDNA mutation rates.
sPROFILER software for N calls analysis
Data from GSEQ base calls was further analysed using
sPROFILER (strand-specific PRObe cell intensity com-
parison for FILtERing). This is a novel algorithm deve-
loped by Kothiyal et al. [35] for improving array call
rates using MATLAB, a numerical computing and pro-
gramming language, over GSEQ call rates, which is
based on intensity signature. When a base cannot be
called because of poor hybridization on one of the
strands, a threshold is determined by using the next
highest intensity ratio on either strand to determine the
base call. sPROFILER helped to resolve >80% of N-calls
from GSEQ and allowed 99.6% of sequence to be
assigned. sPROFILER was designed to not query base
calls conforming to the reference sequence (rCRS), as
GSEQ is conservative in assigning a base call.
Sample size
Sample size was based on detecting the ITPA 94C>A and
IVS2+21A>C polymorphisms in each individual hema-
tological malignancy group using a 1-sided Fishers Exact
Test. We previously determined the frequencies of ITPA
94C>A and IVS2+21A>C polymorphisms in a normal
Caucasian population [3]. For the present study, it was
calculated that a sample size of n= 100 alleles (i.e. 50 pa-
tients) in each disease group would provide 80% power
(p=0.05) to distinguish a raised minimum frequency of
15% for the 94C>A SNP and 25% for IVS2+21A>C. It was
possible to attain sample numbers approaching 50 for the
MDS group (n=39, or 78 alleles), but CLL (n=28, 56
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restricted, thus requiring higher frequencies of the ITPA
sequence variants to attain significance.
Results
Effect of ITPA polymorphic sequence variants on
mitochondrial DNA mutation rates
The study subjects’ anthropometric, types and characteris-
tics are summarized in Table 1 and Table 2. To examine
the effect of reduced ITPase activity on mtDNA, the 13
confirmed AHM patients with the ITPA 94Amutant allele,
comprising 11 heterozygotes and 2 compound heterozy-
gotes, were compared with 4 AHM patients homozygous
for the ITPA 94C wildtype allele (and IVS2+21A wildtype
allele) (Table 2). Peripheral blood or bone marrow samples
were excluded from examination of mtDNA mutation
rates if the intronic ITPA variant (IVS2+21A>C) was pre-
sent, because both homozygotes and carriers exhibit only
partial reduced ITPase activity (Table 1).
Following exclusion of sequence variants signifying
assigned haplogroups, the number of both heteroplasmicTable 2 Adult hematological malignancy patient
characteristics of 17 cell samples selected for study
Attributes MDS CLL AML Control
Number 8 4 1 4
Age (year): 75 (54–90) 68 (37–84) 69 (39–85) 65 (54–79)
median (range)
Sex
(Male/Female)
3/5 3/1 1/0 3/1
Sample type:
Peripheral
blood
7 3 1 2
Bone marrow 1 1 0 2
Classification (n) RAEB-1
(n=1)
CLL (n=4) AMLDN
(n=1)
MDS (n=2,
RCMD & RAEB-2)
RAEB-2
(n=2)
MDP5q
(n=1),
AML (n=1,
AML/TDL)
CLL (n=1)RCMD
(n=2),
MDSU
(n=1)
CMML
(n=1)
Peripheral white cells were randomly selected from 13 patients carrying the
ITPA 94A variant allele and 4 ‘control’ patients homozygous for the ITPA 94C
wildtype allele. MDS: Myelodysplastic syndromes; RAEB: Refractory anaemia
with excess blasts; RCMD: Refractory cytopenia with multilineage dysplasia;
MDP5q: Myelodysplastic syndrome associated with isolated (del)5q
chromosomal abnormality; MDSU: Myelodysplastic syndrome unclassifiable;
CMML: Chronic myelomonocytic leukaemia; AML: Acute myeloid leukaemia;
AML/TLD: Acute myeloid leukaemia with trilineage dysplasia; AMLDN: Acute
myeloid leukaemia with multilineage dysplasia without prior myelodysplasia;
CLL: Chronic lymphocytic leukaemia.and homoplasmic mutations were plotted (Figure 2) and
compared using a Mann–Whitney two-tailed test. This
showed that there were statistically higher numbers of
mtDNA mutations in the patients carrying the ITPA
mutant allele (P < 0.009) than in the patients carrying
the ITPA wild-type allele. For 10 of the 13 patients car-
rying the ITPA 94A allele compared with the 4 patients
lacking this allele, there was a significant increase in
heteroplasmic mtDNA mutations (p < 0.035), as well as
an increase in the number of homoplasmic mutations
but this increase was not significant (p = 0.068)
(Figure 3).
In summary for the 13 AHM patients carrying the ITPA
94A mutant allele, a total of 149 mtDNA nucleotide
changes were detected, including 84 mutations previously
undescribed in the website (http://www.mitomap.org).
This compared with 4 patients homozygous for the ITPA
94C wildtype allele, where a total of 20 mtDNA nucleotide
changes were found, including 12 undescribed mutations
and 7 insertions. Interestingly, the number of mutations in
the tRNA and rRNA encoding regions of the mtDNA of
ITPA deficient patients had increased from zero to a total
of 20 mutations in heteroplasmic and 11 mutations in
homoplasmic mitochondria.
[All the mtDNA changes that were identified for all
AHM patients are available in online Additional file 1:
Tables S1-S3.]+/+
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Figure 2 Total homoplasmic and heteroplasmic mutations in
mtDNA of AHM patients. 13 AHM patients carrying the ITPA 94A
variant allele (i.e. ITPA+/−) comprised MDS (closed circles) n=8, CLL
(open triangles) n=4, AML (open circles) n=1. These were compared
with 4 patients homozygous for the ITPA 94C wildtype allele (i.e. ITPA
+/+), comprising MDS n=2, CLL n=1 and AML n=1. Mutations were
identified against the MitoChip standard mtDNA reference sequence
(rCRS) and those belonging to the assigned mtDNA haplogroup of each
patient excluded. The results are shown as means ± SEM (p < 0.009,
Mann–Whitney two-tailed test).
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Figure 3 Homoplasmic and heteroplasmic mutations in mtDNA of AHM patients. This shows separate analyses of (A) homoplasmic and (B)
heteroplasmic mutations in mtDNA of 13 AHM patients carrying the ITPA 94A variant allele, comprising MDS (closed circles) n=8, CLL (open
triangles) n=4, and AML (open circles) n=1, compared with 4 patients homozygous for the ITPA 94C wildtype allele, comprising MDS n=2, CLL
n=1 and AML n=1. Mutations were identified against the MitoChip standard mtDNA reference sequence (rCRS) and those belonging to the
assigned mtDNA haplogroup of each patient excluded. The results are shown as means ± SEM (p = 0.068 for homoplasmic mutations, not
significant; p < 0.035 for heteroplasmic mutations, Mann–Whitney two-tailed test).
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and heteroplasmic changes (control region, mitochon-
drial ribosomal RNAs, mitochondrial transfer RNAs and
protein genes) comparing AHM patients carrying the
ITPA 94A allele versus the 94C allele. These nucleotide
changes can be calculated as mutational ‘rates’ (number
of base changes per patient). Mutation rates in patients
carrying the ITPA 94A allele appeared higher, particu-
larly in 3 of 4 mtDNA regions (rRNA, tRNA, Prot), but
these differences were not significantly compared to
wildtype ITPA patients.
However, analysis of the frequency of nucleotide changes
among the AHM patients showed they were spread un-
evenly in the entire mtDNA, with a frequency (% mu-
tations per gene) varying from 0.02 - 1.6% (Table 3). In
particular, the MitoChip v2.0 analysis revealed mtDNA
“hotspot regions” in the distribution of mutations when
the ITPA 94C>A sequence variant was present. TheseDlo
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Figure 4 Rates of homoplasmic and heteroplasmic mutations per AH
and (Right) heteroplasmic mutation rates in specific mtDNA regions, for 13
and AML n=1) compared with 4 AHM patients homozygous for the ITPA 94
region; rRNA: mitochondrial ribosomal RNAs; tRNA: mitochondrial transfer R
MitoChip standard mtDNA reference sequence (rCRS) and those belonging
results are shown as means ± SEM (p values not significant, Mann–Whitneyhotspots occurred as raised mean mutation rates in protein
encoded genes MT-ND4, MT-ND5,MT-ND6, MT-CO1,
MT-CO2, MT-CO3,MT-ATP6 and MT-CYB, that may
compromise their activity.
When nucleotide changes in the mtDNA sequences
from both sets of AHM patients were compared for the
reference sequence (Table 3), the mean number of
mtDNA aberrations in AHM patients carrying the aber-
rant ITPA 94A allele (mean = 11.8) was significantly
higher than the patients homozygous for the wildtype
ITPA 94C allele (mean = 5; p < 0.004, Two-way ANOVA).
The observed transitions and transversions in mtDNA
were analysed, and the percentage of each type is shown
in Table 4. G>A/C>T transitions increased by almost
2-fold to 27% in patients carrying the ITPA 94A allele,
compared to 16% in patients homozygous for the ITPA
94C wildtype allele. In contrast, a slight decrease in
A>G/C>T transitions to 59% from 65% was detected inDlo
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M patient affecting specific mtDNA regions. (Left) Homoplasmic
AHM patients carrying the ITPA 94A mutant allele (MDS n=8, CLL n=4
C wildtype allele (MDS n=2, CLL n=1 and AML n=1). D-loop: control
NAs; Prot: protein gene. Mutations were identified against the
to the assigned mtDNA haplogroup of each patient excluded. The
two-tailed test).
Table 3 Mutation rates in mtDNA genes of AHM patients
mtDNA
genes
Patients carrying Patients homozygous for
Gene length ITPA 94A variant allele: mtDNA mutations ITPA 94C wildtype allele: mtDNA mutations
(rCRS) (bp) Mean number SEM Frequency Mean number SEM Frequency
D-Loop 1098 2.23 0.48 0.20 1.50 0.50 0.14
MT-RNR1 954 0.38 0.24 0.04 0.00 0.00 0.00
MT-RNR2 1558 0.85 0.25 0.05 0.00 0.00 0.00
MT-ND1 956 0.15 0.10 0.02 0.25 0.25 0.03
MT-ND2 1042 0.46 0.22 0.04 1.50 0.29 0.14
MT-CO1 1542 0.23 0.17 0.01 0.00 0.00 0.00
MT-CO2 684 0.23 0.12 0.03 0.00 0.00 0.00
MT-ATP6 680 0.54 0.22 0.08 0.25 0.25 0.04
MT-CO3 784 0.31 0.17 0.04 0.25 0.25 0.03
MT-TR 65 0.23 0.17 0.35 0.00 0.00 0.00
MT-ND4L 290 0.08 0.08 0.03 0.00 0.00 0.00
MT-ND4 1378 1.00 0.34 0.07 0.00 0.00 0.00
MT-TS2 59 0.08 0.08 0.13 0.00 0.00 0.00
MT-TL2 71 1.15 0.27 1.63 0.00 0.00 0.00
MT-ND5 1812 1.77 0.34 0.10 1.00 0.41 0.06
MT-ND6 525 0.46 0.22 0.09 0.00 0.00 0.00
MT-CYB 1141 1.46 0.43 0.13 0.25 0.25 0.02
MT-TT 66 0.15 0.15 0.23 0.00 0.00 0.00
Total 14705 11.77* 4.05 0.08 5.00 2.20 0.03
The distribution of mutations in mtDNA genes is shown in 13 patients carrying the ITPA 94A variant allele compared with 4 patients homozygous for the ITPA 94C
wildtype allele. Results shown as number of mutations per gene (mean and SEM) and frequency (% mutations/base). *p < 0.004, using Two-way ANOVA.
Abbreviations of mitochondrial genes according to international notation (www.mitomap.org).
Table 4 Transitions and transversions among
homoplasmic and heteroplasmic mtDNA mutations in
AHM patients
ITPA Total Transitions Transversions
genotype mutations A>G/T>C G>A/C>T
4 homozygous 94C
wildtypes:
Homoplasmic 38 82% 18% 0
Heteroplasmic 11 9% 9% 82%
Total 49 65% 16% 19%
13 carrier 94A
mutants:
Homoplasmic 329 66% 32% 2%
Heteroplasmic 92 33% 8% 59%
Total 421 59% 27% 14%
Mutations shown as total numbers and percent of total, in 13 patients carrying
the ITPA 94A variant allele compared with 4 patients homozygous for the ITPA
94C wildtype allele. ITPA 94A produced 12 unique point mutations; 7 insertions
were also identified.
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a slightly lower decrease in transversions to 14% com-
pared to 19%, among patients carrying the variant ITPA.
N-calls
Failure of the MitoChip v2.0 software to assign a base to
any position is termed a no-call or ‘N-call.’ N-calls were
analysed using two software methods, GSEQ and
sPROFILER (see Methods) for both MitoChip v2.0 sec-
tions (i.e., the reference sequence and common haplo-
types). Table 5 illustrates that the N-calls were slightly
higher for patients carrying the ITPA 94A allele compared
to those homozygous for the ITPA 94C wildtype allele in
both MitoChip v2.0 sections, when GSEQ software deter-
mined the base calls. A significant reduction in N-calls
occurred when further analysed by sPROFILER software
(p < 0.0001 in patients carrying the ITPA 94A allele, and
p< 0.05 in patients were homozygous for the ITPA 94C
wildtype allele).
Further analysis was made of continuous stretches of
N-calls after analysis by sPROFILER software. Short
N-calls stretches of 2–5 undefined bases were found in
AHM patients with and without the ITPA 94A allele
(Figure 5). However, in each of 7 of the 13 patients
Table 5 Mean of N-calls in mtDNA of AHM patients
mtDNA N-calls Patients carrying Patients homozygous for
(MitoChip v.2.0) ITPA 94A variant allele (n=13) ITPA 94C wildtype allele (n=4)
GSEQ sPROFILER GSEQ sPROFILER
rCRS 588 264 p<0.0001 532 234 p<0.05
Additional tiling 6406 4147 p<0.0001 6346 4075 p<0.05
mtDNA from 13 patients carrying the ITPA 94A variant allele compared with 4 patients homozygous for the ITPA 94C wildtype allele. Unique mutations were
identified on the MitoChip v.2.0, and are analysed as those identified by the rCRS section of the microarray vs. the additional tiling section for common
haplotypes. N-calls were analysed using proprietary GSEQ then sPROFILER software; p values calculated using Mann–Whitney test comparing total N-calls
obtained from GSEQ and sPROFILER software.
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longer continuous stretch (6–9 undefined bases) of N-
calls, compared to an absence of longer N-call stretches
in the patients homozygous for the ITPA 94C allele.
Thus only patients carrying the ITPA 94C>A variant
were found to have long continuous stretches of N-calls.
In brief, conventional sequencing of mtDNA samples
with long N-call stretches revealed that the 5 MDS pa-
tients carrying the ITPA 94A variant allele had unique
mutations and insertions compared to the reference
sequence, while no unique mtDNA mutations were
detected in the 2 MDS patients who were homozygous for
the ITPA wildtype allele. Interestingly, our analysis using
Haplogrep software found that there were also 11
haplogroups that were missing 27 expected homoplasmic
variants. All but one of these variants was assigned by the
MitoChip v.2.0 as an N-call.
Association of haematological malignancy with ITPA
polymorphic sequence variant frequency
From the total of 85 AHM patients (170 alleles), 11 were
heterozygous for the ITPA 94A mutant exonic allele, 201 2 3 4 5 6 7 8 9
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Figure 5 Incidence of N-calls following sPROFILER analysis of
the entire mtDNA genome. This illustrates the total distribution of
continuous stretches of N-calls in mtDNA (rCRS section) in both sets
of AHM patients, those carrying the ITPA 94A mutation and those
homozygous for the ITPA 94C wildtype allele. Continuous stretches
of >5 N-calls were re-analysed by conventional sequencing.were heterozygous for the intronic ITPA IVS2+21C mu-
tant allele, 2 were compound heterozygous 94A/IVS2
+21C, and 1 was homozygous IVS2+21C. The overall fre-
quency for these patients for the ITPA 94A mutant allele
(7.7%) was not significantly different from both our pub-
lished frequency [3] and Marsh et al. [13] of 6% for the
allele in normal healthy Caucasian populations. For the
ITPA IVS2+21C mutant allele, the overall AHM frequency
(14.1%) was similar to our published value of 13%.
When the AHM group was then broken down into the
3 disease groups and the frequencies calculated sepa-
rately, the frequencies of the ITPA 94A and the IVS2
+21C alleles were higher for the MDS disease group
(10.3% and 18% respectively) than control populations
but not significantly (p= 0.282 and 0.253 respectively).
For CLL, these frequencies were similar to controls,
while for AML the two mutant alleles were less frequent
but not significantly. Thus the results were not statisti-
cally different for AHM overall, but the ITPA sequence
variants tended to be more frequent for MDS (Figure 6):
a larger study group is required than was available for
this pilot study.
Discussion
Nucleotide imbalance is normally corrected by hydrolytic
nucleotidases [4] and phosphorylases [24], which prevent
accumulation of harmful non-canonical (‘rogue’) nucleo-
tides and nucleosides and their incorporation into DNA,
as well as breaking down and recycling endogenous nucle-
otides [36]. ITPase is one of 4 highly-conserved groups of
nucleotidases that specialize in monitoring rogue nucleo-
tides, the others being the Nudix enzyme superfamily, the
deoxy-UTPases, and the α-nucleotide pyrophosphatase
superfamily.
‘Genotoxic stress’ has been proposed to be an early
event in cell transformation, but the mechanisms for this
have remained unknown [27]. One mechanism of ge-
notoxic stress that has been more widely proposed is
ROS-catalysed oxidation producing rogue nucleotides in
DNA [15,16]. However, it has been shown that accumula-
tion of ITP/dITP can also lead to DNA instability [8].
Reduced ITPase activity produces accumulation of the
rogue nucleotides ITP and dITP, as well as xanthosine
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Figure 6 Frequencies of the ITPA polymorphism in normal Caucasian population compared with three AHM groups. The % frequencies
of the ITPA 94A and IVS2+21C sequence variants are shown. AHM groups examined were MDS (n=39), CLL (n=28), and AML (n=18). The p-values
were calculated using Fisher’s exact test. The frequency for the normal population is from Sumi et al. [3].
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potentially increase the mutational load in mitochondria,
slowly leading towards loss of cellular integrity, with either
of two outcomes: cell death (by apoptosis) or malignancy.
An in vitro study on HeLa cells with a knockdown ITPA
gene has illuminated the role of ITPase in maintaining
DNA integrity and preventing apoptosis in human cells.
The study concluded that absence of functional ITPase
activity caused by ITPA gene defects may lead to DNA
damage and cancer as a consequence of the accumulation
of non-canonical nucleotides [11]. The incorporation of
non-canonical nucleotides arising from drugs can also
affect mtDNA. A recent study by Daehn et al. (2011) de-
scribed the effect of incorporation into human mtDNA of
6-thioguanine, a thiopurine drug concluding that this may
explain some adverse thiopurine reactions including hep-
atotoxicity and myopathy [38], although the study did not
specifically examine ITPase effects.
We therefore considered that chronic genotoxic stress
particularly may affect mtDNA of bone marrow cells,
producing late-onset and pre-cancerous cell transfor-
mation which may progress to cellular constitutional
imbalance and hematologic malignancy. In particular, a
role for ITPA polymorphism in the production of mito-
chondrial DNA mutations has not been previously con-
sidered. We maximized the chances of finding mtDNA
damage by studying high-turnover cells (from bone mar-
row) in older adults. In addition, we aimed to assess the
incidence of the ITPA allelic variants in AHM patients
compared to the normal population.Before mtDNA sequences could be analysed meaning-
fully for mutations, we assigned haplogroups to each of
the patients who were confirmed carriers of the ITPA
94A variant. Removing haplogroup (non-pathogenic)
variants using HaploGrep [33], based on data from
Phylotree [34] revealed unique mutations. The absence
of some expected haplogroup variants was intriguing,
but we were able to assign these absences to the perfor-
mance of the MitoChip array, where they were assigned
as N-calls, as discussed below. After haplogroup correc-
tion, there was a significant increase in the total number
of mutations among 10 of the 13 patients carrying the
ITPA 94A mutant allele, compared with the 4 patients
with wildtype ITPA. However, when homoplasmic and
heteroplasmic mutations were examined separately, only
the heteroplasmic showed a significant increase.
Alterations in mtDNA have been identified and asso-
ciated with solid tumors in bladder, breast, colon, head
and neck, kidney, liver, lung and stomach, and in the
hematologic malignancies leukemia and lymphoma [39].
One study of 104 MDS patients showed a high mtDNA
mutation frequency in the D-loop, transfer RNA and
ribosomal RNA genes, with low mtDNA mutation fre-
quency in protein encoding genes suggesting an associa-
tion of onset of MDS with mitochondrial abnormalities
[40]. About 40% of CLL and AML and 50% of MDS pa-
tients had increased mtDNA somatic point mutations.
The mitochondrial genome comprises 37 discrete genes,
of which the short ‘control region’ (or D-loop), contains
the major elements for mtDNA replication and trans-
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man cancers [41]. Analysis of mitochondrial genes, includ-
ing by microarray based re-sequencing, may represent a
powerful tool for early detection in hematologic malignan-
cies and tumors. For example, research has suggested
there is an increased risk of MDS, CLL and several other
cancers [26,41,42] when mutations occur in the ‘protein-
encoding region’ (or Prot) of mtDNA, which contains 13
genes encoding respiratory chain and oxidative phosphor-
ylation (OXPHOS) enzymes. These genes – NADH de-
hydrogenase (MT-ND), cytochrome c oxidase (MT-CO),
the ATPases (MT-ATP6) and cytochrome b (MT-CYB) –
are highly transcribed. This may leave them more sus-
ceptible to mutational agents, such as rogue nucleotides.
These genes were observed to have a high level of muta-
tions, which may then compromise mitochondrial func-
tion and cellular integrity. On the other hand, there is less
evidence of the involvement of the RNA-encoding re-
gions, containing the genes for 2 ribosomal RNA genes
(rRNA) and 22 transfer RNA genes (tRNA).
Interestingly, our analysis showed that AHM patients car-
rying the ITPA sequence variant had increased rates of both
homoplasmic and heteroplasmic mutations in the rRNA,
tRNA, and protein encoding regions where ITPA wildtypes
had no mutations, compared with mutations frequencies up
to 1.6% in ITPA mutant carriers. The Prot and OXPHOS
regions also showed increases (see Table 3 and Figure 4).
Overall, there was a significant increase in total muta-
tion rates in mtDNA of patients carrying the ITPA 94A
mutation. This implies that the functionality of critical
mitochondrial genes can be compromised by ITP/dITP
accumulation because the high transcriptional activity of
these genes may make them more susceptible to muta-
tional agents such as rogue nucleotides. The role of
ITPase in cellular surveillance of rogue nucleotides may
thus have late-onset effects in humans, with ITPA gene
defects having consequences for genomic stability.
The case of ITPase-deficient mice has provided direct
in vivo evidence that deoxy-ITP (dITP) can be incorpo-
rated at high levels into DNA, resulting in death before
weaning [8]. Furthermore, Spee et al. [43] demonstrated
in vitro that when dITP was added to dNTPs in PCR
amplification of the 171 bp Lactococcus lastis nisZ gene,
numerous point mutations were generated. In addition,
the type of mutation generated occurring appears to be
consistent: for Lactococcus, the major point mutations
generated by dITP were transitions (60% A>G/T>C and
26% G>A/C>T), with only 14% transversions and low
frequencies of insertions or deletions. Kamiya et al. [44],
using transfection of mutant ITPA into NIH-3T3 cells,
showed that deoxy-xanthosine exclusively induces G>A
transitions in mammalian cells by introducing deoxy-
xanthosine into a synthetic gene. This was confirmed
again by Kamiya et al. [45] when they utilized DNAsynthesis experiments with synthetic templates contai-
ning xanthine and hypoxanthine - which form the rogue
nucleotides dXTP and dITP - to show that G>A and
A>G transitions were generated, demonstrating that
these nucleotides can be highly mutagenic [46].
These results match well with our findings (Table 4).
There was a 2-fold increase in the percentages of total
G>A/C>T transitions accompanied by a slight percent
decrease of A>G/T>C transitions in mtDNA of patients
carrying the ITPA 94A mutant allele, compared to patients
who were wildtype for ITPA. Transversions were slight-
ly decreased. This suggested mutational selectivity in
mtDNA transitions caused by low activity (<25% normal)
of ITPase.
Transversions are base changes resulting from purine-
pyrimidine substitutions or vice versa, in theory caused
by misincorporation following oxidation/deamination of
DNA bases by ROS. The rise in G>A/C>T transitions
were caused in theory by misincorporation of rogue nu-
cleotides, such as dITP. However, the detection of any
expected insertions or deletions (‘indels’) arising from
the presence of the ITPA 94A polymorphism was ini-
tially limited by the nature of the MitoChip v.2.0 and
GSEQ software, which is not designed to detect indels.
Yet deletions were of particular interest, given that de-
letion/depletion is common in other mitochondrial
metabolism disorders such as thymidine phosphorylase
(MNGIE), thymidine kinase (TK2) and deoxy-guanosine
kinase (dGK) deficiencies [25,47].
The MitoChip’s GSEQ software has no provision for
detecting either insertions or deletions, assigning them
as ‘N-calls.’ We predicted that indels may be assigned as
‘N-calls’ by the GSEQ software, and in particular that
the frameshift produced by an indel may result in a
length of adjacent N-calls. Therefore, continuous stret-
ches of N-calls in the MitoChip reference sequence
section were examined in depth, using a second base-
assignment software sPROFILER, which was designed to
reduce the number of N-calls [45].
When we used sPROFILER software, it produced a
significant drop in N-calls in both patient sets (Table 5).
In particular, we observed continuous stretches of
N-calls - ranging from 6 to 9 bases – only among AHM
patients carrying the ITPA 94A mutant allele (Figure 5).
Thus by using sPROFILER we managed to narrow the
search area for any sequence variants or indels to be
then analysed by conventional sequencing. By focusing
on the longest stretches of N-calls in each sample we
were able to identify unique sequence variances and in-
sertions [48]. Deletions were not found, which points to
a mutational mechanism for low ITPase that varies from
that of, of example, MNGIE. This finding supported our
hypothesis that the presence of the ITPA 94C>A
sequence variant may lead to an increase in mtDNA
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quently cause insertions/deletions, particularly among
MDS patients.
Finally, we considered whether ITPA deficiency might
be causative of some forms of adult (i.e. late-onset)
haematological malignancy (AHM). We found that the
frequencies of ITPA variant alleles for the 3 (Caucasian)
AHM groups examined were raised for MDS and CLL –
but not statistically different – when compared to the
normal Caucasian population. For AML – one of the
mixed-lineage leukemias – ITPA variants were at a lower
frequency than normal (Figure 6). In retrospect, our
study would have been underpowered to detect a signifi-
cant contribution of reduced ITPase activity to the
pathogenesis of AHM, especially as ITPA polymorphism
may be only one of several causative factors for a rogue
nucleotide-driven DNA repair pathology that predispose
to DNA instability. However, we suggest that the ob-
served trends warrant screening of larger numbers of
MDS patients in particular.
The reduced frequency of mutant ITPA that we ob-
served for AML may point towards a similar mechanism
as reported for MLL, but this requires further study.
ITPA is one of 5 genes noted to be up-regulated in adult
mixed-lineage leukemias [10], which is associated with
therapy-related AML. Treatment for CLL with the pur-
ine (rogue) analogue fludarabine in combination chemo-
therapy achieves high response rates, but has also been
associated with treatment related MDS and AML in up
to 10% [49]. It is therefore possible that ITPA may be in-
volved in genetic instability leading to these secondary
marrow disorders, although we could not make any firm
conclusions from our present study.
Conclusion
Significant changes in the levels of total mtDNA muta-
tions found when the ITPA 94A mutant allele was present;
indicate that reduced ITPase activity in humans may not
be as benign as previously considered. The nature of these
mtDNA mutations, i.e. predominantly G>A/C>T transi-
tions, were consistent with our hypothesis that these were
induced by deoxy-ITP/XTP rogue nucleotides. Insertions
were also found among some of the MDS patients. The
role of ‘house-cleaning’ genes in cell transformation re-
mains to be investigated further, but our small study pre-
sents evidence towards a new paradigm to explain the
early stages of cellular transformation leading to adult ma-
lignant disease.
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